NewsRoom Articles - Page 577 of 602

ThursdaySep 21, 2017 4:10 pm

Algae Dynamics Corp. (ADYNF) Collaborates with University of Western Ontario

Research finds that higher levels of the brain chemical GABA can reverse negative effects such as schizophrenia and depression Professor Steven Laviolette, who spearheaded the study, hopes that GABA-increasing cannabinoid compounds developed with industrial partners from this research could lead to clinical trials “in the next few years” Algae Dynamics Corp. has signed a collaborative agreement with the University of Western Ontario, giving the company the patent rights to any drugs developed as a result of research Algae Dynamics Corp. (OTCQB: ADYNF) is in a collaboration agreement with the University of Western Ontario (now rebranded as Western University), which is…

ThursdaySep 21, 2017 3:00 pm

India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials

Four drug candidates in the pipeline Potential sales of Alzheimer’s drugs run to billions Hyalolex heading for clinical trials India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed at reducing the buildup of amyloid β-peptide (Aβ) plaques on neurons in the brain, a process that causes the crippling cognitive complaint known as Alzheimer’s disease. Alzheimer’s afflicts more than five million Americans, and, so far, no effective cure for this form of dementia has…

WednesdaySep 20, 2017 3:25 pm

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) is “One to Watch”

Amid a continued boom in the growing cannabis sector, Canada is moving rapidly toward legalization as the U.S. continues to foot drag at the federal level, leading many sector analysts to conclude that it’s the Canadian companies who might benefit the most as an underlying shift toward medical and recreational use continues. Out of a tiny handful of just 58 Health Canada-licensed producers, vertically integrated Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) stands out as a one of the fastest growing cultivators and pharma developers, having also obtained authorization to produce cannabis oils. While sales of dried marijuana intended for smoking…

WednesdaySep 20, 2017 10:07 am

The Green Organic Dutchman Rides on Quality Medical Cannabis, Private Placement and Strong Leadership

The Green Organic Dutchman (“TGOD”), a 100-percent owned subsidiary of The Green Organic Dutchman Holdings Ltd., produces high-quality medical marijuana. Its organic medical cannabis is farm grown and pesticide-free. There are many factors in favor of the company. The demand in a legal national market, consumer preference for organic foods and products of all kinds and a recent $20 million private placement are all positive signs. Also, TGOD is among a select group of companies licensed to cultivate medical cannabis by Health Canada under the Access to Cannabis for Medical Purposes Regulations. Those interested in investing should contact TGOD directly…

TuesdaySep 19, 2017 4:10 pm

The Green Organic Dutchman Holdings Ltd. Announces $20M Private Placement as Company Moves toward Expansion

Company has, to date, raised $41.5 million and has more than 2,400 shareholders Has one of the largest licensed land parcels in Canada, situated on 100 acres Offers organically grown, pesticide-free medical marijuana under Canada’s ACMPR The Green Organic Dutchman Holdings Ltd. (“TGOD”), a Canadian company engaged in producing farm-grown, high-quality organic medical cannabis using craft growing, all natural, organic principles, announced on September 11 (http://cnw.fm/jHbs0) that it has entered into an agreement with a syndicate led by PI Financial Corp. to complete a private placement offering of units. The syndicate will offer, on a commercially reasonable effort basis, 4,242,500…

TuesdaySep 19, 2017 3:33 pm

At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles

Producer of consistent, standardized medicinal cannabis Menu of cannabis strains with varying CBD:THC ratios ABcann’s CBD-Med is one of Canada's highest-CBD products In an interview with Cantech Letter (http://cnw.fm/g2AtB), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis…

MondaySep 18, 2017 3:08 pm

India Globalization Capital, Inc. (NYSE: IGC) Reports Promising Progress of Cannabis-Based Alzheimer’s Drug Candidate

IGC is the only publicly traded cannabis stock with patent filings for treating Alzheimer’s disease Company has a first-mover advantage in phytocannabinoid-based combination therapy Alzheimer’s is America’s most expensive disease, costing the country an estimated $259 billion in 2017 It is considered America’s most expensive disease, projected to cost an estimated $259 billion in the United States in 2017 and as much as $1.1 trillion by 2050 (http://cnw.fm/L9huG). It is not cancer, and it is not AIDS. It is Alzheimer’s disease. This devastating chronic neurodegenerative disease is the most common cause of dementia among older adults and is the sixth-leading…

FridaySep 15, 2017 9:31 am

ChineseInvestors.com, Inc. (CIIX) Sets Goal of Greater than 100% Gain in FY2018 Revenues

In FY2017, the company’s investor relations business grew 130%, and its subscriptions business rose by 57% Warren Wang, founder and chief executive officer of CIIX, sets goal of greater than 100% gain in sales in FY2018 and cost-cutting to achieve profitability Company excited about its expansion of auxiliary services into the digital currency industry; Wang says that market will offer long-term opportunities ChineseInvestors.com, Inc. (OTCQB: CIIX) recorded a skyrocketing 76% year-over-year operating revenues increase for its fiscal year ended May 31, 2017. The company’s two divisions exhibited double-digit and triple-digit growth in FY2017. The investor relations business grew 130%, while…

ThursdaySep 14, 2017 2:31 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology

Proprietary biosynthesis process to produce cannabinoids Provisional patent application filed Cost-effective methodology to produce trace cannabinoids If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind. Known worldwide for his investing prowess, Warren Buffett has said, “I don't want a business that's easy for competitors. I want a business with a moat around it with a very valuable castle in the middle” (http://cnw.fm/ehB50). Naturally, the Sage of Omaha was…

WednesdaySep 13, 2017 3:58 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract,…

News and publishing service for cannabis related companies

Contact us: 512.354.7000